<DOC>
	<DOCNO>NCT02866786</DOCNO>
	<brief_summary>Polycystic ovary syndrome ( PCOS ) one common endocrine disorder woman reproductive age lead cause infertility due anovulation . Oral contraceptive pill ( OCPs ) consider first line medical therapy regularize menses woman PCOS . However may worsen metabolic profile patient elevate insulin resistance already derange PCOS . As high prevalence insulin resistance Indian woman PCOS , insulin sensitiser like metformin may beneficial . Hence study undertaken compare combine effect metformin OCPs clinical , hormonal , metabolic ovarian ultrasonographic characteristic patient PCOS evaluate whether combination drug advantageous OCPs metformin alone improve clinical metabolic profile .</brief_summary>
	<brief_title>The Effects OCP Metformin Clinical , Hormonal , Metabolic Ultrasonographic Characteristics PCOS</brief_title>
	<detailed_description>We aim enroll 120 patient fulfil Rotterdam diagnostic criterion PCOS study . Patients baseline clinical examination ( Body weight , Body mass index , Waist circumference , Hirsutism score ) , hormonal profile ( FSH , LH , fast Insulin/glucose ratio , DHEAS , testosterone level ) , metabolic profile ( fast 2 hour post prandial plasma glucose , total cholesterol , HDL cholesterol , LDL cholesterol , triglyceride level ) , ultrasound examination ( ovarian volume subcapsular follicle count , stromal echogenicity ) doppler blood flow study ( ovarian stromal velocity , Pulsatility index , Resistivity index , Systolic/Diastolic ratio stromal vascularization index ) . Patients randomize use computer generate randomization program two group accord BMI ( &lt; 25 &gt; 25 ) . The randomization stratify order achieve homogenous distribution PCOS patient arm study respect age body mass index . Each group subdivide three treatment arm . 1st treatment arm receive OCP contain 35 microgram ethinyl estradiol 2 mg cyproterone acetate cyclically ( 21 day regimen ) daily ; 2nd treatment arm receive OCP contain 35 microgram ethinyl estradiol 2 mg cyproterone acetate cyclically ( 21 day regimen ) 3rd treatment arm receive OCP plus metformin 500 mg twice daily period six month . Each patient ask keep diary menstrual period study period . The patient follow 3 6 month treatment evaluate change mention parameter . Analysis data do descriptive perceptive statistical method use Statistical Package Social Sciences ( SPSS ) software .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Patients include study fulfill Rotterdam diagnostic criterion ( 2003 ) PCOS . Current previous use oral contraceptive , glucocorticoid , antiandrogens , ovulation induction agent , antidiabetic antiobesity drug hormonal drug . Medical surgical treatment PCOS previous 3 month Presence endocrinopathies ; except treat hypothyroidism stable replacement dos thyroid hormone Pregnancy , breastfeed desire pregnancy study interval ( 6 month ) Inability understand proposal study preclude effective informed consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>